HDAC inhibitors in models of inflammation-related tumorigenesis.
Histone deacetylase (HDAC) inhibitors have been described in detail for their anti-proliferative potency. Recently, an anti-inflammatory property was characterized in vitro and in vivo. This dual efficacy of HDAC inhibitors is highly attractive, since chronic inflammations such as ulcerative colitis are associated with an increased risk of developing carcinomas. Additionally, in models of colitis and inflammation-induced tumorigenesis inflammation as well as tumor development was significantly inhibited by HDAC inhibitor treatment. The mechanisms involved reach beyond the simple regulation of histone acetylation and deacetylation. The currently known key target structures and mechanisms mediating this dual effect will be discussed in this review.
Glauben
Rainer
R
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Medical Department I, Berlin, Germany.
Sonnenberg
Elena
E
Zeitz
Martin
M
Siegmund
Britta
B
D000107:Acetylation; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000276:immunology; D003092:Colitis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D016328:NF-kappa B / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D016588:Anticarcinogenic Agents; D056572:Histone Deacetylase Inhibitors; D016328:NF-kappa B; D006655:Histone Deacetylases